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ECOG Baseline Visit 1 Visit 2 Visit 3 Visit 4
0 12.3 14.7 13.6 13.8 12.7
1 16.4 15.5 14.6 14.1 15.2
2 17.6 17.8 16.3 16.1 16.9
3 n/a 22.4 22.8 19.6 20.7
p-value 0.0002 0.0017 <0.0001 0.0048 0.0011
N 132 98 77 66 49
 
Conclusions: Retrospective analysis of trial data suggests that PSALC 
is a reliable, valid, and responsive scale for measuring SCLC symp-
toms. If feasible in SCLC population, a prospective validation study 
could be used to further evaluate the validity of this symptom scale.
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Background: Post-translational modiﬁcations in the tails of nucleoso-
mal core histones are emerging as important signalling processes con-
trolling a wide variety of functions. Indeed they play a crucial role in 
chromatin packaging, gene expression and genome stability. Therefore, 
perturbation of this epigenetic information is likely to be involved in 
the development of cancer. Although some studies identiﬁed an altered 
activity of histone-modifying enzymes in tumors, little is known about 
the post-translational modiﬁcations of histones in these malignancies. 
Methods: By using immunohistochemistry, we studied the pattern of 
histone H4 modiﬁcations in a series of 100 primary non small cell lung 
tumors comprising 51 squamous carcinoma and 49 adenocarcinoma. 
Speciﬁc antibodies recognizing acetylated histone H4 at positions K5, 
K8 and K16 and trimethylated histone H4 at position K20 were used 
on frozen tissue sections with an automated immunostainer Ventana in 
order to standardize the staining. Normal lung epithelial cells (al-
veolar and bronchial basal cells) were taken as internal controls and 
their score used for determination of the cut off score to discriminate 
between positive (score at least equal to normal) and negative (score 
lower than normal) cases. 
Results: Our data show that, as compared to normal lung, lysines 5 
and 8 of histone H4 are hyperacetylated in 48% and 40% of all tumors 
respectively, more frequently in squamous carcinoma than in adenocar-
cinoma (p=0.009 and p=0.0002 respectively). In contrast, acetylation 
at Lys16 and trimethylation at Lys20 are lost in 52% and 47% of the 
tumors respectively. Across histological types loss of trimethylation at 
Lys20 is more frequent in squamous carcinoma than in adenocarcinoma 
(p=0.0002), is associated with advanced stage (p=0.018) and nodal 
metastasis (p=0.01) and correlates with a poor survival among stade 
I (p=0.026). Importantly, in adenocarcinoma, loss of trimethylation 
at Lys20 is associated with advanced stage (p=0.006) and correlates 
with a poor survival among stage I-II (p=0.0001) and N0 versus N1-2 
(p=0.013) tumors. Furthermore, the double loss of acetylation at Lys16 
and trimethylation at Lys20 is associated with a shorter survival in 
these patients as compared to the presence of either one or none of 
these alterations. 
Conclusion: These data provide the ﬁrst evidence of a global aberrant 
pattern of histone H4 modiﬁcation in lung tumors with hyperacety-
lation of Lysines 5 and 8 and loss of acetylation of lysine 16 and of 
trimethylation of Lysine 20. The frequent loss of lysine 20 trimethyl-
ation in squamous carcinoma, independently of the stage, suggests that 
it could be an early event in the carcinogenesis of this tumor type. In 
contrast, loss of lysine 20 trimethylation is less frequent in adenocar-
cinoma but correlates with a poor prognosis suggesting a role in the 
progression of these tumors.
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Background: In the development of cancer, a series of tumor suppres-
sor genes is inactivated by point mutation and chromosomal deletion. 
Aberrant methylation of CpG islands has recently been shown to serve 
as an alternative way of inactivating such genes in cancer. Methylation 
of cytosine residues in CpG dinucleotides is an extremely important 
epigenetic modiﬁcation of the eukaryotic genome that affects vari-
ous cell processes. Methylation is known to play an important role in 
neoplasia by inactivating tumor suppressor genes such as Rb, p16, and 
estrogen receptor. In this study we used CpG island ampliﬁcation and 
suppression subtractive hybridization to identify the aberrant methyla-
tion of CpG islands in A/J mouse lung adenoma, in order to clarify 
whether a hypermethylated homologue gene exists in human pulmo-
nary adenocarcinoma.
Methods: NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone)-
induced A/J mouse lung adenoma and normal tissue were used in this 
study. The histology of A/J mouse adenoma mimics the early stage of 
human pulmonary adenocarcinoma. The genomic DNA was extracted 
using standard procedures. The PCR-based methylated CpG island am-
pliﬁcation (MCA) technique was used for detection of methylated CpG 
islands. Suppression subtractive hybridization (SSH) and differential 
screening (DS) were used to identify the differentially methylated se-
quence in A/J mouse lung adenoma tissue. For the genes selected after 
SSH and DS analysis, quantitative Real-time PCR was used to check 
their expression level in A/J mouse lung adenoma tissue and normal tis-
sue. Using homoloGene software, human homologue genes were then 
detected. Real-time PCR was also performed to check the expression 
level of these genes in human lung adenocarcinoma and normal lung 
tissue. Bisulﬁte genomic sequencing was done to conﬁrm the methyla-
tion status of these genes in the promotor area.
